ADC Therapeutics SA (NYSE:ADCT – Get Free Report) has received an average rating of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $7.50.
ADCT has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of ADC Therapeutics in a research report on Monday, April 15th. Guggenheim reaffirmed a “buy” rating on shares of ADC Therapeutics in a research report on Friday, April 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Thursday, March 14th.
Get Our Latest Stock Analysis on ADC Therapeutics
Institutional Trading of ADC Therapeutics
ADC Therapeutics Stock Down 2.3 %
Shares of NYSE:ADCT opened at $4.34 on Monday. The company has a market cap of $359.41 million, a price-to-earnings ratio of -1.48 and a beta of 1.73. The firm’s 50-day simple moving average is $4.62 and its 200-day simple moving average is $2.69. ADC Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $6.04.
ADC Therapeutics (NYSE:ADCT – Get Free Report) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.56). The company had revenue of $16.79 million for the quarter, compared to analysts’ expectations of $16.58 million. ADC Therapeutics had a negative return on equity of 1,313.37% and a negative net margin of 344.15%. On average, research analysts forecast that ADC Therapeutics will post -2.2 EPS for the current year.
ADC Therapeutics Company Profile
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Featured Articles
- Five stocks we like better than ADC Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Stocks Leading the U.S. Agriculture Comeback
- Health Care Stocks Explained: Why You Might Want to Invest
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How to Most Effectively Use the MarketBeat Earnings Screener
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.